

Comparative Evaluation of ALT & AST Levels of Hepatitis B and C Infected Pregnant Women in Lahore, Pakistan

Ibrar Ahmad¹, Hakeem Jan², Salman Munir Malik¹, Qaisar Ali^{3*}, Ihteshamul Haq^{1*}, Ishtiaq Hassan¹, Ikram Ullah¹, Ahmed Raza⁴, Awais Shaukat⁴, Fawad Khalid⁵, Noman Rehmat⁶, Fazal Shan⁷, Authar Hussain⁸

Department of Biotechnology and Genetic Engineering, Hazara University Mansehra, KP, Pakistan

Department of medical laboratory Technology, Imperial College of Businesses studies Lahore

*Department of Medical laboratory technology, Premier institute of health and Management sciences, Pakha Gulam, Kaka khail town Peshawar
University of the Punjab Lahore

Saidu Medical College Saidu Sharif Swat KPK Pakistan

Department of Allied Health Sciences, Gomal University D I Khan

Department of medical laboratory Technology, National Institute of Health Islamabad

Department of Molecular Biology & Genetics, Khyber medical University Peshawar

Corresponding Author

Name: Qaisar Ali: Email address: qaisarali6@gmail.com

Co-Corresponding Author:

Ihteshamul Haq

Email Address: Ihteshamulhaq384@gmail.com

Abstract:

During pregnancy viral Hepatitis may cause maternal complication which may lead to still birth. Pakistan is the second country in the world having high prevalence of chronic hepatitis B and C infections alongside the highest fertility rate therefore chances of vertical transmission and pregnancy complications are high primarily due to compromised liver functions. The aim of this study was to screen the hepatitis B and C virus infected pregnant women in Lahore and to monitor their liver function enzymes (ALT & AST). From January 2018 to December 2018, 15000 pregnant females in different areas of Lahore were screened by ICT method for Hepatitis B surface antigen (HBsAg) and Hepatitis C antibodies (Anti HCV). Positive samples are confirmed by ELISA. ALT and AST of hepatitis B, hepatitis C infected and healthy pregnant women were estimated. 149 pregnant females out of 15000 were positive for HCV and 45 cases were diagnosed positive for HBV. ALT and AST of these viral infected females were compared with healthy pregnant females. In HCV analysis, the values of ALT and AST were significant. Paradoxically, the HBV analysis revealed insignificant differences of these estimated enzymes. Hence, statistically co-infection of Hepatitis B & C indicates significant ALT while insignificant AST. The present study confirms the low endemically prevalent Hepatitis B & C infections among

pregnant women in Lahore, Pakistan. HCV elevate ALT and AST levels among pregnant women while during HBV infection they remain within normal range.

Key words: Hepatitis, Pregnancy, ALT, AST.

Introduction:

Presence of inflammatory cells in liver is called Hepatitis which may lead to the liver Cirrhosis or Hepatocellular Carcinoma. Mostly etiology of Hepatitis is viruses particularly Hepatitis B and C virus[1]. These viruses are blood-borne pathogens and can be transmitted either horizontally or vertically. Prior transmission eventuates via contaminated needle sticking, tattooing, blood and blood products transfusion, razors and unsterilized dental or other surgical equipment. Other body fluids including seaman, saliva, menstrual and virginal secretions can also transmit these viruses. Hepatitis B virus can survive up to 7 days in environment which also increases its virulence. Both of the viruses have long incubation periods and have no particular sign and symptoms until become chronic which makes them difficult to diagnose in early stages of infection[2,3]. Hepatitis viruses only enter into hepatocytes due to presence of special molecules on the surface on hepatocytes which act as virus receptors[4]. These viruses can elevate serum Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) enzymes which are associated with liver damage. These Aminotransferases especially serum AST level also excrete from skeletal muscle and cardiac muscle therefore these enzymes are not always associated with liver damage [5].

In 2015, enigmatically around 257 million people are infected by Hepatitis B and 71 million people are diagnosed as Hepatitis C positive which causes 1.34 million deaths annually across the world. Unlike other endemic diseases like malaria, tuberculosis and HIV, the mortality rate of viral Hepatitis is inflating which has been increased by 22% since 2000[6]. Pakistan has second highest population of chronic hepatitis B and C in the world [7] which is alarming condition where 150 000 new cases are diagnosed positive every year. The number of Hepatitis B and C patients has reached to 12 million in the country [8]. In Pakistan HCV prevalent equally in both genders but HBV has more men victims than women[9]. Women having viral hepatitis can develop severe maternal complications even fetal deaths during pregnancy. Hepatitis B virus has high vertical transmission rate than HCV [10]. Hepatitis B can transmit vertically if mother is chronic carrier or develop infection during last stage of pregnancy[11]. While transmission of HCV depends on the viral load in pregnant mother[12]. Treatment of hepatitis B is different during pregnancy because Hepatitis B immunoglobulin and vaccinations are not enough to reduce the risk of vertical transmission that's why other anti-viral drugs may also be prescribed. The treatment of Hepatitis C involves variation in pregnant women than that of normal patients [13,14].

Symptoms	Hepatitis		
	A	B	C
Dark urine	✓	✓	✓
Stomach/abdominal pains		✓	✓
Jaundice (yellowing of the skin/eyes)	✓	✓	✓
Pale or clay-colored stool	✓		✓
Fever	✓	✓	✓
Loss of appetite	✓	✓	✓
Fatigue	✓	✓	✓
Nausea/vomiting	✓	✓	✓
Aching joints		✓	

Symptoms of Hepatitis A, B and C

Material and Methods:

Samples are collected from different areas of Lahore in the period of one year, from January 2018 to December 2018. A fixed questioner is used to select the females who have same sociodemographic (age, locality, occupation). 3ml samples are collected in gel vacutainers and transport to college laboratory maintaining the temperature of the samples from 4°C to 6°C. Serum is separated after centrifugation and Hepatitis C antibodies (anti HCV) and Hepatitis B surface antigen (HBsAg) are screened by immunochromatography (ICT) method and Accurate cassettes (USA) are used. As a result positive samples are confirmed by ELISA method. Liver enzymes (ALT, AST) are estimated automatically on BACKMAN COULTER AU680.



MAP OF Lahore City Pakistan

Statistics: Data is repeatedly checked and then analyzed by T test using statistical package for social science (SPSS) version 16.0. The co-infection is analyzed by using one way ANOVA. The P value <0.05 is considered as significant.

Ethics: The study is approved by the ethics committee of Imperial College of Business Studies Lahore while the consent is taken from the targeted population.

Results:

Out of 15000, we met with 149 positive HCV cases (0.99%) and 45 HBV positive cases (0.3%) among the pregnant studied population. These retrospective HCV & HBV Patients we also gauged their ALT and AST Levels, respectively. We also included control referral group (n=150) while cross checked with HCV and HBV infected individual. ALT and AST of both control group and infected groups (HBV & HCV) are noted and been compared. In first comparison where ALT are noted as 49.00 ± 32.89 and 34.87 ± 9.25 in both HCV and control group (<0.001) respectively whereas AST is 56.32 ± 41.59 in HCV group and 42.68 ± 24.81 in control group (0.001). Both AST and ALT are noted as incomparable or significant parameters between the HCV and control groups (Table 1).

Table 1: HCV infection in pregnant women and their association with AST, ALT

Variables	HCV POSITIVE	CONTROL	P Value
ALT	49.62 ± 32.82	34.87 ± 9.25	<0.001
AST	56.32 ± 41.59	42.68 ± 24.81	0.001

ALT and AST are taken by mean \pm SD, Independent t-test was used for noticing the significant p-value (<0.05) of both AST and ALT between HCV positive and control individuals among the pregnant women studied population.

(HCV) Hepatitis C virus , (ALT) Alanine aminotransferase, (AST) Aspartate aminotransferase

Moreover, HBV infection in the reflection of control group, ALT is noticed as 39.84 ± 18.04 VS 34.87 ± 9.25 P=0.42 whereas, AST is 44.37 ± 18.92 . VS 42.68 ± 24.81 P = 0.92, respectively. Therefore in HBV infection and control group comparison ALT and AST are found insignificant (>0.05) (Table 2).

Table 2: HBV infection in pregnant population and their association with AST, ALT

Variables	HBV POSITIVE	CONTROL	P Value
ALT	39.84 ± 18.04	34.87 ± 9.25	0.42
AST	44.37 ± 18.92	42.68 ± 24.81	0.95

ALT and AST are taken by mean \pm SD, Independent t-test was used for noticing the significant p-value (<0.05) of both AST and ALT between HBV positive and control individuals among the pregnant women studied population.

(HBV) Hepatitis B virus , (ALT) Alanine aminotransferase, (AST) Aspartate aminotransferase

In addition, apart from control group both the infected groups i.e. HBV and HCV were analyzed together by using one way-ANOVA in order to know the significant contribution of both ALT and AST comparatively. Interestingly, we found ALT (49.62 ± 32.82 VS 39.84 ± 18.04) in both HCV and HBV group significant (0.03) whereas AST were noticed insignificant in both the HCV and HBV groups (56.32 ± 41.59 VS 44.37 ± 18.92 ; $P = 0.08$, respectively) (Table 3).

Table 3: Healthy controlled

Variables	HCV	HBV	P Value
ALT	49.62 ± 32.82	39.84 ± 18.04	0.03
AST	56.32 ± 41.59	44.37 ± 18.92	0.08

ALT and AST are taken by mean \pm SD, one way ANOVA was used for noticing the significant p-value (<0.05) of both AST and ALT between HCV positive and HBV Positive individuals among the pregnant women studied population.

(HCV) Hepatitis C virus, (HBV) Hepatitis B Virus, (ALT) Alanine aminotransferase, (AST) Aspartate aminotransferase.

DISCUSSION:

Screening of viral hepatitis is important to decrease the risk of hepatitis prevalence and to avoid the complications of viral hepatitis in pregnant women. During pregnancy, screening of HCV and HBV is important to reduce the risk of vertical transmission. Our study reveals that HCV infect 0.99 % pregnant females of Lahore and HBV 0.3% pregnant females, which is lower than previous studies. In 2001 the prevalence of hepatitis C in pregnant women in Lahore was studied in which 6.0% females were diagnosed positive [15] and in 2008 the prevalence of hepatitis B and C were 2.2% and 7.3% respectively [16]. Decrease in infected pregnant females' number in our study is due to decrease in the transmission of virus by syringe or through blood transfusion in Lahore. In 2009 hepatitis B infect 1.61% female population in Lahore that is now decrease to 0.3% in pregnant females because of vaccination of hepatitis B [17]. Another reason of decrease number in pregnant females with viral hepatitis is the awareness to avoid pregnancy during infection. Irshad Ahmad (2016) studied the prevalence of HCV and HBV among pregnant females in Peshawar, Pakistan where 1.16% females were HCV infected and 1.22% females were HBV infected [18]. Another recent study show the prevalence of HCV and HBV in pregnant women of KPK is 1.67% and 2.22% respectively [19]. Where in Karachi, the prevalence

of hepatitis B is 0.34%, which is approximately equal to our study (0.3%) [20]. Prevalence of viral hepatitis is low in Lahore and Karachi because the health care facilities are better there than Khyber Pakhtoonkhawa (KPK) and other regions of Pakistan.

In India the prevalence of hepatitis B during pregnancy was 1.2% which is three times higher than our study [21] while in 2006 HCV prevalence was 1.03% which is also higher than our results [22]. Comparing with the other regions of the world the prevalence of HBV is much higher 18.2% and 7.2% respectively in the pregnant women of Zaria [23] and Kano [24], Nigeria. These differences in result may be due to difference in groups which has difference in risk factor for infection, availability of vaccination and endemicity of infection in region. Result of HCV in pregnant women of Lahore is low as compare to the normal persons of South East Asia (2.15%), Europe (1.03%) and America (1.17%) [25].

In early stages, viral hepatitis is usually asymptomatic but it can be assessed by alteration in ALT and AST blood levels. Increase in these Aminotransferases enzyme levels is high in HCV as compare to HBV [26]. During pregnancy levels of ALT and AST remain within normal range [27]. But patients with HCV has increased ALT levels during pregnancy [28]. In our study ALT levels are also raised in HCV infection but remain within normal range in HBV infection. AST also represent the same variation in both infections that its value increase in HCV but not in HBV. A study on HBV infected pregnant females' exhibit normal ALT levels [29]. Another study on pregnant females having HCV also shows elevated ALT level [30] which resemble to our results both in hepatitis B and C cases. In another study pregnant females having HBV are diagnosed with normal ALT levels which support the results of our study [31]. In this study statically when we combine the both HCV and HBV infections in pregnant women using one way ANOVA than ALT elevate but AST remains within normal range.

Conclusion:

This study conclude that HCV and HBV are low endemically prevalent in the pregnant women of Lahore with the percentage of 0.9% and 0.3% respectively which is comparatively low than the other areas of Pakistan and less prevalent ratio than previous studies which indicates the improvement in transmission precautionary methods. HCV causes the elevation in ALT and AST during pregnancy but in HBV pregnant females the values remain within normal limits. Statically women having both HCV and HBV infections can exhibit increase ALT and normal AST values which can be estimated in future studies.

References:

1. Qamar, Z., Anwar, F., Ahmad, R., Haq, I., Khan, A. M. K., Hussain, R., ... & Khan, J. (2021). Prevalence of Hepatitis C virus and determination of its genotypes in subjects of Tehsil Daggar District Buner, KP, Pakistan. *Clinical Epidemiology and Global Health*, 12, 100809.2. Organization WH (2016) Hepatitis C (fact sheet no. 164, updated July 2013).

2. Anwar, F., Khan, M., Salman, M., Ahmad, S., Ullah, F., Khan, J., ... & Abbas, M. (2021). Seroprevalence of hepatitis B virus in human population of district Buner Khyber Pakhtunkhwa Pakistan. *Clinical Epidemiology and Global Health*, 10, 100688.
3. Bashir, Z., Ahmad, S. U., Kiani, B. H., Jan, Z., Khan, N., Khan, U., ... & Mahmood, T. (2021). Immunoinformatics approaches to explore B and T cell epitope-based vaccine designing for SARS-CoV-2 Virus. *Pak. J. Pharm. Sci*, 34(1), 345-352.4. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, et al. Binding of hepatitis C virus to CD81. *Science*, (1998); 282(5390): 938-941
4. Haq, I., Ullah, R., Din, M., Ahmad, S., Anwar, F., Ali, M., & Khan, H. U. (2020). Unrecognized HIV infection in asymptomatic volunteer blood donors at district Peshawar, Khyber Pakhtunkhwa, Pakistan. *New Microbes and New Infections*, 35, 100685.
5. Anwar, F., Tayyab, M., Salman, M., Abdullah, Din, M., Khan, J., & Haq, I. (2020). Dengue outbreak 2018 in district Shangla KPK; clinical features and laboratory markers of dengue virus infection. *Future Virology*, 15(10), 693-699.
6. Haq, I., Muhammad, A., Fazli Zahir, M. K., Anwar, F., Akhtar, M. S., & Ullah, F. (2020). Serological and Epidemiology study of Helicobacter pylori infection among Dyspeptic patients in District Peshawar Pakistan. *Adv. Biores*, 11(3), 81-85.7. Farhat M, Yasmeen A, Ahmad A An Overview of Hepatitis B and C in Pakistan. Chapter: Book Name. 2014 of publication; 1;
7. Anwar, F., Tayyab, M., Khan, J., & Haq, I. (2020). COVID-19 and taking care and protection of patients with intellectual disabilities, need special care and equity.
8. Anwar, F. (2020). Serological and Epidemiological Evaluation of active HCV Infection in the Volunteer blood Donor at District Swat Khyber Pakhtunkhwa Pakistan. *Bull. Env. Pharmacol. Life Sci*, 9, 08-15.
9. Shah, I. A., Anwar, F., Haq, I. U., Anwar, Y., Aizaz, M., & Ullah, N. (2018). HBV burden on population, a comparative study between two districts Mardan and Charsadda of KPK, Pakistan. *International Journal of Contemporary Research and Review*, 9(09), 20269-20274.10. Michielsen P, Van PD. Viral hepatitis and pregnancy. *Acta gastro-enterologica Belgica*, (1999); 62(1): 21-29.
10. ul Haq, I., Khan, M., Rehman, Z., Anwar, F., Ullah, H., & Ullah, N. (2018). HBV prevalence in the volunteer blood donors in Peshawar, Khyber Pakhtunkhwa Pakistan. *Int J Biosci*, 13(5), 50-54.
11. ul Haq, I., Khan, M., Rehman, Z., Anwar, F., Ullah, H., & Ullah, N. (2018). HBV prevalence in the volunteer blood donors in Peshawar, Khyber Pakhtunkhwa Pakistan. *Int J Biosci*, 13(5), 50-54.
12. Ohto H, Terazawa S, Sasaki N, Sasaki N, Hino K, et al. Transmission of hepatitis C virus from mothers to infants. *New England Journal of Medicine*, (1994); 330(11): 744-750.
13. Brown RS, McMahon BJ, Lok AS, Wong JB, Ahmed AT, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis. *Hepatology*, (2016); 63(1): 319-333.

14. Arshad M, El-Kamary S, Jhaveri R. Hepatitis C virus infection during pregnancy and the newborn period—are they opportunities for treatment? *Journal of viral hepatitis*, (2011); 18(4): 229-236.
15. Zafar M, Mohsin A, Hussain I, Shah A. Prevalence of hepatitis C among pregnant women. *J Surg Pak*, (2001); 6(6): 32-33.
16. Asia B, Bano KA, Misbah-ul-Islam K, Riaz H. Antenatal screening of women for hepatitis B and C in an out-patient department. *Journal of the Dow University of Health Sciences*, (2008); 2(1): 32-35.
17. Nafees M, Farooq M, Jafferri G. Frequency of hepatitis B and C infections in the general population of Lahore, Pakistan. *Biomedica*, (2009); 25:106-111.
18. Ahmad I. Prevalence of hepatitis B and C viral infection among pregnant women in Peshawar, Pakistan. *Hepatitis monthly*, (2016); 16(6).
19. Khan MY, Saleem A, Jabbar A, Rehman HU, Khan M. Ratio of Hepatitis B and Hepatitis C viral infection in pregnant women of Haripur KPK, Pakistan. *BioMedicine and Surgery*, (2017); 1(2): 73-76.
20. Sheikh SM. Hepatitis B and C: value of universal antenatal screening. *J Coll Physicians Surg Pak*, (2009); 19(3): 179-182.
21. Pande C, Sarin SK, Patra S, Bhutia K, Mishra SK, et al. Prevalence, risk factors and virological profile of chronic hepatitis B virus infection in pregnant women in India. *Journal of medical virology*, (2011); 83(6): 962-967.
22. Kumar A, Sharma KA, Gupta R, Kar P, Chakravarti A. Prevalence & risk factors for hepatitis C virus among pregnant women. *Indian Journal of Medical Research*, (2007); 126(3): 211.
23. Mirambo MM, Mbena PB, Mushi MF, Mtebe M, Moremi N, et al. Prevalence of hepatitis B surface antigen among pregnant women attending antenatal clinic at Nyamagana District Hospital Mwanza, Tanzania. *Tanzania Journal of Health Research*, (2016); 18(1).
24. Dawaki S, Kawo A. Seroprevalence of Hepatitis B surface antigen (HBsAg) in pregnant women attending an urban maternity hospital in Kano, Nigeria. *J Microbiol*, (2006); 20705-709.
25. Stasi C, Silvestri C, Voller F, Cipriani F. The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine. *Journal of infection and public health*, (2016); 9(4): 389-395.
26. Marcellin P. Hepatitis C: the clinical spectrum of the disease. *Journal of hepatology*, (1999); 31:9-16.
27. Bacq Y, Zarka O, Brechot J, Mariotte N, Vol S, et al. Liver function tests in normal pregnancy: a prospective study of 103 pregnant women and 103 matched controls. *Hepatology*, (1996); 23(5): 1030-1034.
28. Paternoster DM, Fabris F, Palù G, Santarossa C, Bracciante R, et al. Intra-hepatic cholestasis of pregnancy in hepatitis C virus infection. *Acta obstetricia et gynecologica Scandinavica*, (2002); 81(2): 99-103.

29. Nguyen G, Garcia R, Nguyen N, Trinh H, Keefe E, et al. Clinical course of hepatitis B virus infection during pregnancy. *Alimentary pharmacology & therapeutics*, (2009); 29(7): 755-764.
30. Ferrero S, Lungaro P, Bruzzone BM, Gotta C, Bentivoglio G, et al. Prospective study of mother-to-infant transmission of hepatitis C virus: a 10-year survey (1990–2000). *Acta obstetrica et gynecologica Scandinavica*, (2003); 82(3): 229-234.
31. Han G-R, Cao M-K, Zhao W, Jiang H-X, Wang C-M, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. *Journal of hepatology*, (2011); 55(6): 1215-1221.